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Despite the advances achieved in understanding the molecular biology of muscle
cells in the past decades, there is still need for effective treatments of muscular
degeneration caused by muscular dystrophies and for counteracting the muscle wasting
caused by cachexia or sarcopenia. The corticosteroid medications currently in use for
dystrophic patients merely help to control the inflammatory state and only slightly
delay the progression of the disease. Unfortunately, walkers and wheel chairs are the
only options for such patients to maintain independence and walking capabilities until
the respiratory muscles become weak and the mechanical ventilation is needed. On
the other hand, myostatin inhibition, IL-6 antagonism and synthetic ghrelin administration
are examples of promising treatments in cachexia animal models. In both dystrophies and
cachectic syndrome the muscular degeneration is extremely relevant and the translational
therapeutic attempts to find a possible cure are well defined. In particular, molecular-based
therapies are common options to be explored in order to exploit beneficial treatments
for cachexia, while gene/cell therapies are mostly used in the attempt to induce a
substantial improvement of the dystrophic muscular phenotype. This review focuses on
the description of the use of molecular administrations and gene/stem cell therapy to treat
muscular degenerations. It reviews previous trials using cell delivery protocols in mice and
patients starting with the use of donor myoblasts, outlining the likely causes for their poor
results and briefly focusing on satellite cell studies that raise new hope. Then it proceeds
to describe recently identified stem/progenitor cells, including pluripotent stem cells and
in relationship to their ability to home within a dystrophic muscle and to differentiate into
skeletal muscle cells. Different known features of various stem cells are compared in this
perspective, and the few available examples of their use in animal models of muscular
degeneration are reported. Since non coding RNAs, including microRNAs (miRNAs), are
emerging as prominent players in the regulation of stem cell fates we also provides an
outline of the role of microRNAs in the control of myogenic commitment. Finally, based
on our current knowledge and the rapid advance in stem cell biology, a prediction of clinical
translation for cell therapy protocols combined with molecular treatments is discussed.
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INTRODUCTION
Muscular dystrophies are heterogeneous genetic diseases caused
by progressive degeneration of skeletal muscle fibers (Emery,
2002). Mutations in genes encoding for crucial skeletal muscle
proteins located either at the plasma membrane (i.e., dystrophin-
glycoprotein complex) or, less frequently, within internal cellular
membranes are responsible for those disorders. The lack of those
proteins increases the probability of damage during contraction
and eventually leads to fiber degeneration (Blake et al., 2002;
Gumerson and Michele, 2011). Despite the extensive literature
reported on this topic, the molecular mechanisms responsible for
the progressive muscular degeneration are not yet understood in
detail. Physiologically, muscular fiber degeneration is counterbal-
anced by the regeneration of new fibers formed at the expense of
resident myogenic cells and usually each degeneration process is
followed by a new regenerative cycle. Skeletal muscle regeneration
is mainly sustained by satellite cells (Mauro, 1961), local myo-
genic progenitors localized underneath the basal lamina of muscle
fibers (Tedesco et al., 2010).
When it is damaged, a muscle undergoes a remodeling process
and the resident myogenic cells differentiate into myofibroblasts
to produce extracellular matrix (ECM), which is required for
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the adequate tissue repair. Following repeated cycles of degenera-
tion/regeneration, such myofibroblasts accumulate in the muscle
producing large amounts of ECM proteins and thus ultimately
leading to fibrosis. However, after repeated injuries, the satellite
cells in the muscles become exhausted, losing their regenerative
capacity. In this view, the genetic manipulation of satellite cells
could potentially guarantee an improvedmuscle regeneration and
function. In this review we provide information about the differ-
ent sources of myogenic stem cells, highlighting their common
features and characteristics as well as their controversies in the
therapeutic approaches. Advantage and disadvantage for autolo-
gous and heterologous cell therapy will be discussed, considering
the different sources of myogenic stem cells.
Alterations in skeletal muscle homeostasis can result in either
atrophy or hypo-metabolism. Etiologically, the molecular deter-
minants responsible for such metabolic changes are known as
common players in different muscular wasting diseases. In this
view, they represent promising therapeutic targets common to
the wide range of the known muscular diseases that could deter-
mine a strong impact in terms of prognosis, clinical setting and
management. Pharmacotherapy still represents the most com-
mon strategy adopted to counteract muscle wasting for a large
spectrum of muscular diseases such as cancer mediated cachexia,
Rheumatoid Arthritis (RA) and sarcopenia, while muscular dys-
trophies can also be potentially treated by a multi-therapeutic
approach based on gene/cell therapies combined with molecular
treatments.
PATHOPHYSIOLOGY AND CLINICAL RELEVANCE OF MUSCLE
WASTING
The state of progressive loss of muscular and fat mass known
as cachexia syndrome is a condition associated with several
chronic diseases such as AIDS, cancer, chronic obstructive lung
disease, multiple sclerosis, congestive heart failure, sepsis, dia-
betes, RA and tuberculosis (Laviano et al., 2003; Fearon et al.,
2011). According to its multifactorial and complex nature, as
well as to both the pathophysiologic and epidemiologic features
of its primary-related disease, such syndrome depicts a worse
global epidemiologic scenario if compared with the other mus-
culoskeletal disorders. The dramatic effects that cachexia have
on the prognosis are well-known in clinical management of can-
cer diseases. According with the Global Burden Diseases (GBD)
estimations, up to 50% of the oncologic patients suffer from
cachexia and up to 80% of them show clear signs of cachexia in
the late stages of cancer progression (Laviano et al., 2003; Fearon
et al., 2011; Suzuki et al., 2013).Moreover, cancer-related cachexia
counteracts the efficacy of radio- and chemotherapeutic treat-
ments by increasing their side effects and decreasing patient’s
quality of life (Tisdale, 2002). Such complications are directly reli-
able for a high percentage of mortality in cancer patients, about
20–40%, accounting for more than 2 million of global premature
deaths for year (Bruera, 1997).
Among the wide range of the muscular diseases that affect
musculoskeletal system by hampering respiratory and locomotive
functions, RA, dystrophies and cachexia syndrome represent the
most common and are considered as a serious problem for human
health. In 2010 GBD estimates showed that musculoskeletal
disorders accounted for more than 150,000 deaths, with an incre-
ment of 121% between 1990 and 2010 (Lim et al., 2012).
The progressive skeletal muscle weakness and wasting are
the main prognostic features exhibited by the heterogeneous
musculoskeletal disorders (Leung and Wagner, 2013) (Figure 1).
Although musculoskeletal diseases and cachexia have different
origins (due to genetic alterations the first and to complications of
several chronic diseases the latter), body weight loss, muscle atro-
phy, fatigue, weakness and loss of appetite are common clinical
features observed in both. Nevertheless, while many autoimmune
diseases ultimately result in a cachectic state of the patients, they
are often associated with unintentional weight loss. RA is an
autoimmune disease where the energetic balance is normal and
eventually fat mass is increased. Thus, RA is a unique example of
autoimmune disease in which cachexia is not associated with a
general body-wide wasting and depends exclusively on the reduc-
tion in the muscle mass that might be responsible in lowering
the average survival of the patients. Therefore, muscle wasting is
the key player responsible for the induction of muscle atrophy in
musculoskeletal disorders, which is triggered by catabolic events
occurring into the affected skeletal muscle tissue (Figure 1). At
the molecular level, this is due to an unbalance between pro-
tein anabolism and catabolism in favor of proteolysis of some
crucial proteins occurring into the muscle fibers, mediated by
the expression of muscle-specific ubiquitin ligase (E3 protein)
atrogin1/MAFbx and MuRF1 (Bodine et al., 2001; Gomes et al.,
2001).
Beyond the basic action of mechanic contraction, the skeletal
muscle is a tissue involved in many other metabolic activities such
as glucose, glycogen and lipid metabolism (Jensen and Richter,
2012), as well as endocrine (Pedersen and Febbraio, 2008) and
immunogenic activities (Nielsen and Pedersen, 2008). Such bio-
logical heterogeneity reflects the histological diversity observed
into the skeletal muscle tissue and, in turn, highlights mul-
tifaceted possibilities for the therapeutic interventions. It has
been recently demonstrated that the microenvironment outside
the myofibers can actively participate to the cancer-mediated
muscle wasting. This happens when circulating tumor factors
induce muscle damage by activation of both satellite and non-
satellite muscle progenitor cells, and such process is followed by
inhibition of their myogenic differentiation due to a persistent
expression of Pax7 (He et al., 2013). On the other hand, the
metabolic complexity of the skeletal muscle also renders it sus-
ceptible to environmental stimuli. Epidemiological studies show
indeed the potential role of environmental and lifestyle factors
(i.e., physical activity, diet and sun exposure) on the increas-
ing susceptibility of the insurgence of sarcopenia (Scott et al.,
2011). Overall, studies focused on the investigation of the general
molecular mechanisms responsible for muscle wasting identified
some potential therapeutic targets involved in the main catabolic
pathways and that could be inhibited by pharmacological and by
gene- or cell-therapy based approaches. Specifically, we will dis-
cuss pharmacological strategies aimed to counteract the effects
of pro-inflammatory stimuli (i.e., TNF-α, IL-6) in cachexia, sar-
copenia and RA, as well vector-based micro-dystrophin transfer,
oligonucleotide-induced exon-skipping and cell therapy strat-
egy based on the use of healthy myogenic cell precursors [i.e.,
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FIGURE 1 | Pathological heterogeneity of muscle wasting. Descriptive
model of muscle degeneration in chronic diseases. Loss of muscle mass,
decrease of fiber size and myonuclear content, reduction of contraction force
and increase of fibrosis (white net) are common pathophysiological features
of muscle degeneration mediated by changes into the biological process
(white arrows) triggered by muscle diseases.
satellite cells, side population (SP), fibro-adipogenic progenitors
(FAPs), mesoangioblasts, ES, and iPS cells] in dystrophinopathies
(Figure 2).
PHARMACOLOGICAL APPROACH
Lack or alteration of structural proteins into the musculoskele-
tal system causes chronic inflammation. Although there are no
specific cures for muscle wasting mediated by the different forms
of muscular dystrophies and cachexia, pharmacotherapy has been
the first historical clinical approach used tomodulate the progres-
sion of such diseases (Abdel-Hamid and Clemens, 2012) by coun-
teracting chronic inflammation (Figure 2). Because dystrophin
plays a crucial role in preserving the integrity of the muscu-
lar membrane by permitting the anchorage of the dystrophin-
associated protein complex, lack or genetic mutations of dys-
trophin result in a chronic influx of calcium into the myofibers,
causing cellular death and inflammatory responses. In addition,
fibrosis can occur to replace the damagedmuscular fibers, causing
muscle weakness (Figure 1). Pilot studies performed in patients
affected by Duchenne/Becker and Limb-Girdle muscular dys-
trophies (DMD, BMD, and LGMD respectively) based on the
administration of non-steroidal anti-inflammatory drugs, such as
ibuprofen and nabumetone, or on the use of isosorbide dinitrate,
a NO donor vasodilator, showed an improvement of the general
pathophysiologic conditions (Figure 2). This effect was medi-
ated by a deregulation of circulating level of TGF-β (D’Angelo
et al., 2012), a known mediator of fibrosis in dystrophinopathies
(Goldstein and Mcnally, 2010). Corticosteroids have been pro-
posed as a pharmacological therapy for dystrophinopathies, in
order to counteract muscle necrosis, inflammation and to reduce
the muscle membrane susceptibility to damage (Abdel-Hamid
and Clemens, 2012). In particular, prednisone (Griggs et al.,
1991, 1993; Bonifati et al., 2000) and deflazacort (Bonifati et al.,
2000) induce improvement and a long-term stabilization of
the muscle strength (Bonifati et al., 2000), as well as a sub-
stantial reduction of weakness progression in DMD patients
(Moxley et al., 2005). Moreover, since the elevation of cytoso-
lic calcium concentration can trigger apoptotic and/or necrosis
events in the dystrophic muscles, such physiological alteration
represents another important glucocorticoid-based therapeu-
tic target. Recently, studies in preclinical models proposed α-
methylprednisolone, administrated either alone (Ruegg et al.,
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FIGURE 2 | Treatments of muscle diseases. Representative scheme of the
main therapeutic approaches adopted to counteract muscle wasting.
Pharmacotherapy aims to maintain muscle integrity by neutralization of
ubiquitin-proteasome pathway (UPP), provoked by circulating
pro-inflammatory stimuli (i.e., TNF-α and Il-6). Administration of non-steroidal
anti-inflammatory drugs (NSAID, green), fenofibrates and steroids (STEDS,
blue) reduces the overall expressions of atrogenes. It also stimulates utrophin
expression and regulates the cytosolic homeostasis of NO and Ca++
elements, while drug-like molecules (red) and antibiotics (green) provide the
“read-through” strategy to obtain semi-functional dystrophin protein. To date,
NSAID and STEDS are the most diffused drugs to treat dystrophinopathies,
cachexia syndrome, rheumatoid arthritis and sarcopenia. Gene therapy is
experimentally adopted for dystrophinopathies treatments. Such method is
based on the use of Adeno-associated viruses (AAV) and lentiviral vectors to
mediate the delivery of micro-dystrophin or mini-utrophin and by use of exon
skipping strategy to increase the endogenous expression of dystrophin (see
text). Skeletal Myogenic Precursors (SMPS), Side Population (SP),
Fibro-Adipogenic Progenitors (FAPs) and Mesoangioblasts (MABs) are
potential candidates for cell therapeutic approaches of dystrophinopathies.
MABs were recently enrolled in PhaseI/II clinical trial either for their ability to
repopulate the endogenous pool of satellite cells and for their myogenic
differentiation capability to produce dystrophin.
2002) or in combination with taurine (an aminoacid with antiox-
idant properties), as a candidate for pharmacological regulation
of the cytosolic calcium flux in dystrophic muscles (Cozzoli et al.,
2011).
The pharmacological efforts aiming to counteract muscle
degeneration in dystrophinopathies mainly point to stabilize the
muscular membrane integrity. This is the case of drugs designed
to increase the expression level of native utrophin, as a mecha-
nisms used to compensate for the dystrophin lack (Tinsley et al.,
1998; Gilbert et al., 1999). Nabumetone is a novel promising
small molecule with anti-inflammatory properties (COX1 and
2 inhibitor) that in vitro can activate the promoter of the A
isoform of utrophin (Moorwood et al., 2011). The adminis-
tration of aminoglycosides antibiotics (i.e., Gentamicin, NB54)
(Barton-Davis et al., 1999; Politano et al., 2003; Nudelman et al.,
2009) and read-through compounds such as RTC13, RTC14
(Kayali et al., 2012), or ataluren (PTC124) (Hamed, 2006; Finkel,
2010) has been proposed as a new strategy to induce ribo-
somal read-through of premature termination mutations, to
obtain a full-length dystrophin protein in patients with DMD
and Becker Muscular Dystrophy (BMD) (Figure 2). Various pro-
inflammatory stimuli are involved in cancer mediated muscle
wasting (Todorov et al., 1996; Suzuki et al., 2013), RA (Gomez-
Sanmiguel et al., 2013) and sarcopenia (Malafarina et al., 2012).
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In this case the pharmacological approaches used so far aim to
counteract the biological activity of secreted pro-inflammatory
mediators, such as interleukins (Il-1β, IL-6), interferon gamma
(IFN-γ), tumor necrosis factor alpha (TNF-α) (Todorov et al.,
1996) and proteolysis inducing factor (PIF) (Todorov et al.,
1999). Unfortunately, anti-cytokine therapy aimed to block
TNF-α by administration of Infliximab (monoclonal TNF anti-
body) or Etanercept (soluble TNF-α receptor) in cancer patients
showed only poor ameliorative effects on cachexia pathophysi-
ology (Gueta et al., 2010; Wu et al., 2013), whereas in patients
with RA mediated cachexia, Etanercept was shown to reduced
mortality (Morgan et al., 2014) and ameliorate the muscular
function (Marcora et al., 2006). Indomethacin showed anti-
cachectic effects in muscles from tumor bearing mice by inducing
reduction in the levels of NF-kappaB, TNF-α and IL-6 (Zhou
et al., 2003). Notably, dithiocarbamate inhibits IL-6 synthesis
(Nai et al., 2007). Other treatments proposed in in vivo mod-
els in order to counteract oxidative and inflammatory burden
in cancer-mediated muscle wasting are based on administration
of glycine (Ham et al., 2013), simvastatin (Palus et al., 2013),
eicosapentaenoic acid (Vaughan et al., 2012) and use of pro-
teasome inhibitors to block the ubiquitin-proteasome pathway
(Zhang et al., 2013). Such treatments efficiently counteract the
expression of genes associated with the muscle protein break-
down observed in cancer cachexia (i.e., Atrogin-1 and MuRF-
1) On the contrary, fenofibrate, a PPARα agonist (Castillero
et al., 2011), and α-Melanocyte-stimulating hormone (α-MSH)
(Gomez-Sanmiguel et al., 2013) ameliorate the pathophysiology
of muscles in an adjuvant-induced arthritis rat model by pre-
venting the overexpression of Atrogin-1, MuRF-1, and myostatin
observed in RA (Castillero et al., 2011; Gomez-Sanmiguel et al.,
2013). Pharmacological treatments used to counteract the pro-
gressive loss of skeletal muscle mass observed in sarcopenia are
based on the administration of ghrelin, testosterone, Growth
Hormone (GH), myostatin inhibitors and supplementation of
vitamin D (Malafarina et al., 2012). Therapeutically, despite the
efforts spent so far for sarcopenia treatment, only few results have
been achieved in terms of increased muscle mass and strength,
and decrease of muscle catabolism. Because vitamin D levels
decrease with elderly, promising results were obtained in dietary
supplementation of vitamin D in aged people, specially in muscle
functional improvement (Malafarina et al., 2012).
GENE THERAPY
Gene replacement strategy was historically conceived to counter-
act the lack of dystrophin that affects DMD and BDM patients.
Transgenic mice (mdx), dogs with X-linked muscular dystro-
phy (GRMD), and non-human primates (cynomolgus macaques)
are examples of animal models extensively used to test novel
methods for dystrophin gene delivery. Adeno-associated viruses
(AAV) and lentivirus based vectors mediate efficient delivery
of micro-dystrophin or mini-utrophin (Cerletti et al., 2003)
and provide an alternative option for dystrophin-deficient mdx
mouse (Gregorevic et al., 2004, 2006; Yoshimura et al., 2004;
Liu et al., 2005; Rodino-Klapac et al., 2007), in non-human pri-
mate animal models (Rodino-Klapac et al., 2007) and Golden
Retriever Muscular Dystrophy (GRMD) dogs (Cerletti et al.,
2003; Sampaolesi et al., 2006; Koo et al., 2011). Nevertheless, all
the dystrophin delivery methods proposed so far showed poor
restoration of dystrophin within a small area of the skeletal muscle
tissue targeted and only a partial improvement of the contractile
properties (Rodino-Klapac et al., 2013) (Figure 2). Since dele-
tions of single or multiple exons in the dystrophin gene are
the most pathogenic mutations in DMD and BDM, antisense-
mediated exon skipping (Douglas and Wood, 2013) represents
a promising additional strategy adopted to increase dystrophin
expression in DMD and BDM models, by restoring the genetic
reading frame. Notably, this can be obtained either by single-
(Van Deutekom et al., 2007; Jorgensen et al., 2009; Kinali et al.,
2009) or multi-exon skipping approaches (Aartsma-Rus et al.,
2006; McClorey et al., 2006; Goyenvalle et al., 2012). So far, many
antisense oligonucleotide, such as morpholino oligomers (PMOs)
and 2′O-methylphosphorothioate oligoribonucleotides (2′OMe),
have been synthetized and successfully tested both in vitro and in
vivo (Benedetti et al., 2013). They act by targeting of specific exons
allowing their skipping during the splicing of dystrophin mRNA
(Figure 2). In 2007 van Deutekom and colleagues tested the
ability of PRO051oligonucleotide to restore dystrophin into the
tibialis anterior of 4 DMD patients. In 2009 Kinali and colleagues
treated the extensor digitorum brevis of 7 DMD patients with
morpholino splice-switching oligonucleotide (AVI-4658) (Kinali
et al., 2009). These trials provided evidences for local restora-
tion of dystrophin in the treated muscles and for the safety of the
protocols adopted (Van Deutekom et al., 2007).
However, because myoastin negatively affects skeletal mus-
cle growth, AAV-mediated gene delivery of myostatin inhibitors
(i.e., MRPO) has been proposed as a therapeutic strategy to
maintain muscle mass (Morine et al., 2010) and improve the
contraction force (Qiao et al., 2008) in both mdx mice (Qiao
et al., 2008; Morine et al., 2010) and dogs (Qiao et al., 2009).
Noteworthy, gene therapy AAV-mediated approaches were also
used to restore structural, such as sarcoglycans (Sampaolesi et al.,
2003), and non-structural proteins (Goonasekera et al., 2011). In
fact, it is known that cytosolic alteration of Ca2+ flux observed
in muscular dystrophies leads to sarcolemmal instability. This
could be reduced by overexpressing the sarcoplasmic reticulum
Ca2+ ATPase 1 (SERCA1) in both mdx and δ-sarcoglycan-null
(Sgcd−/−) mice (Goonasekera et al., 2011). Preclinical studies
about the therapeutic applications of AAV-based gene deliv-
ery strategies were also performed to treat RA (Dai and Rabie,
2007). In particular, because the synovial lining is poorly trans-
duced, subsynovial muscle tissues have been predominantly
transfected in various RAmodels to investigate the effects of anti-
inflammatory mediators such as IL-4 (Cottard et al., 2000) and
IL-10 (Apparailly et al., 2002) either in mice (Cottard et al., 2000;
Apparailly et al., 2002) as well as in human and murine synovial
cell lines (Katakura et al., 2004).
CELL THERAPY
As already previously mentioned, satellite cells are quiescent
unipotent stem cells, located underneath the basal lamina of adult
skeletal muscle fibers (Mauro, 1961). They are formed during
the second wave of embryonic myogenesis after which they exit
the cell cycle, contributing significantly to the first post-natal
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muscle growth (Gros et al., 2005; Kassar-Duchossoy et al., 2005;
Relaix et al., 2005). In case of muscle damages, satellite cells can
re-enter the cell cycle resulting in an increasing number of myo-
genic progenitors able to fuse and form newmuscle fibers (Huard
et al., 2002; Jarvinen et al., 2005; Tedesco et al., 2010; Wang and
Rudnicki, 2012). Given their natural commitment, it has been
easy to consider satellite cells as the leading candidate for mus-
cle regeneration in dystrophic mice (Partridge et al., 1989). In the
case of transplantation of individual fibers into the tibialis ante-
rior of irradiated mdx mice (specific treatment used to remove
the existing population of satellite cells), satellite cells of the fiber
donor expand, repopulating the endogenous pool, and differ-
entiate into functional myofibers. Pax7+/CD34+/GFP+ satellite
cells, isolated from the diaphragm of Pax3::GFP mice, proved a
good cellular model for the treatment of irradiated mdx muscles,
resulting in restoration of the expression of dystrophin in many
skeletal fibers and reconstitution of the pool of resident satellites
cells (Montarras et al., 2005) (Figure 2). It has been shown by
in vivo imaging that a single CD34+/integrinα+ satellite cell can
replenish the resident satellite pool that, in the presence of further
damage, can quickly re-enter a newwave of proliferation, generat-
ing new myofibers (Sacco et al., 2008). Fifty years of studies about
the role of stem cells in skeletal muscle regeneration have identi-
fied a complex pattern of expression for surface markers within
the endogenous pool of satellite cells (Rinaldi and Perlingeiro,
2013). Specific subpopulations of satellite cells positive for CD34
(Beauchamp et al., 2000), M-cadherin (Irintchev et al., 1994),
α7β1-integrin (Burkin and Kaufman, 1999; Gnocchi et al., 2009),
syndecan-3/4 (Cornelison et al., 2004), the chemokine recep-
tor CXCR4 (Ratajczak et al., 2003) barx2 (Meech et al., 2012)
and caveolin-1 (Volonte et al., 2005) have been identified and
investigated for their in vitro, as well as in vivo, therapeutic
potential.
The intra-muscular injections, however, have revealed some
significant problems. One of the major limitations on the use of
satellite cells in therapy is the cell heterogeneity. The variable rate
of satellite cell homing after transplantation of a single myofiber
could be due to the cell heterogeneity and their functional niche
of origin. Moreover, satellite cells show limited migratory abil-
ity, reduced myogenic capacity when expanded in vitro, while the
host immune rejection still represents a major issue when satel-
lite cells are used for transplantation (Mouly et al., 2005; Kuang
and Rudnicki, 2008). Nevertheless, many others methodological
issues concerning intramuscular cell transplantation of myogenic
stem cells in the treatment of dystrophinopathies have been par-
tially solved by a further basic knowledge of the skeletal muscle
stem cell biology, achieved in the recent years by both clinical and
pre-clinical data (Hill et al., 2006; Skuk and Tremblay, 2011; Brack
and Rando, 2012).
Recently, interesting results have been obtained by the prospec-
tive isolation of skeletal myogenic precursors (SMPS) (Figure 2),
a distinct population of the satellite cells pool, characterized
by the expression of Cxcr4 and β1integrin and the absence of
CD45, Sca1 and Mac1(Sherwood et al., 2004). Once injected into
immunodeficient mdx muscles, SMPS contribute to the muscle
regeneration (up to 94%) and to the satellite cell pool. SMPS need
to be injected freshly isolated, in order to have beneficial effects.
Although their migratory capacity remains limited to the areas
surrounding the site of injection, the contractile force of limb
muscles was significantly higher in the treated mice compared to
controls (Cerletti et al., 2008).
A subpopulation of progenitors associated with skeletal mus-
cles is a so-called SP. SP cells are defined as myogenic cells
SCA1+/ CD45+ (Polesskaya et al., 2003; Seale et al., 2004), unable
to retain the intercalating Hoechst 33342 dyes (Gussoni et al.,
1999; Polesskaya et al., 2003; Montanaro et al., 2004). When
co-cultured with myoblasts, they can fuse to form myotubes
in vitro and, if injected into the femoral artery in mice mdx5cv
mice, can contribute up to 5–8% of the regenerated fibers
(Perez et al., 2009). Remarkable results were obtained with the
isolation of a rare subset (0.25%) of SP cells, identified as
SCA1+/ABCG2+/Syndecan4+/Pax7+ cells (Tanaka et al., 2009).
Once injected, those cells in muscle treated with 1.2% BaCl2
regenerate up to 30% of the fibers and, surprisingly, reconstitute
up to 75% of the endogenous satellite pool (Tanaka et al., 2009).
However, the muscle damage induced by BaCl2 is not a com-
monly accepted model of regeneration and this must be taken
into account when interpreting these results. Another class of
myogenic precursor was isolated from the population of endothe-
lial cells in human muscles, through the prospective isolation
of cells by FACS CD56+/CD34+/CD144+ (Okada et al., 2008).
These myoendothelial progenitors, after injection into injured
muscle of SCID mice can be grafted into existing muscle fibers
and form neofibres (Tamaki et al., 2002). A population of muscle-
interstitial cells, referred to as FAPs, was recently identified. FAPs
have been shown to mediate the beneficial effects of histone
deacetylase inhibitors (HDACi) in mdx mice (Mozzetta et al.,
2013). HDACi are known as promoters of endogenous regener-
ation and functional recovery of dystrophic muscles in the mdx
mouse. They act by increasing the fiber size and reducing both
the fibrosis and the fat deposition (Minetti et al., 2006). FAPs iso-
lated from young dystrophic subjects show a minimal myogenic
commitment that can be implemented by HDACi at the expense
of their fibro-adipogenic potential. In addition, HDACi enhance
FAPs ability to promote differentiation of adjacent satellite cells
(Figure 2).
In recent years, a new class of stem cells associated with vascu-
latures and termed mesoangioblasts (MABs) have been studied
as potential therapeutic protocols to threat dystrophic muscles
(Figure 2). MABs were originally isolated from the dorsal aorta
of the embryo (E9.5) (Minasi et al., 2002) and then from adult
skeletal muscles in mice, dogs, and humans (Tonlorenzi et al.,
2007; Quattrocelli et al., 2012). MABs are positive for several
markers, including CD34, SMA, Pdgfrα, Pdgfrβ, Ng2, and AP,
supporting the hypothesis that they belong to a subgroup of per-
icytes. MABs are multipotent as highlighted by their myogenic,
osteogenic, chondrogenic, and adipogenic differentiation poten-
tial observed in quail-chick chimeras and in vitro and in vivo
experiments in mouse model. After intra-arterial injection in dys-
trophic muscles of Scga-null mice or GRMD dogs, MABs are able
to regenerate (up to 50%) muscle architecture, with function-
ality (Sampaolesi et al., 2006). Similarly, promised results were
obtained with the transplantation of human MABs in immunod-
eficient mdx mice (Sampaolesi et al., 2003). Building up on those
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promising preclinical studies a Phase I/II clinical trial of donor
mesoangioblasts transplantation from HLA-identical donors in 5
DMD patients is nearing completion (EudraCT Number: 2011-
000176-33). However, due the ethical rules, several limitations are
present in this first attempt of stem cell systemic delivery in DMD
patients. First, the age of the patients and progression of the dis-
ease were advanced in the enrolled patients. Second, cell dose was
quite low, from 1/5 to 1/10 of that administered to the GRMD
dogs. Third, injections were limited into the femoral arteries, con-
fining the cell treatment mainly to the muscles downstream the
femoral artery. Taken into account those limitations, this trial will
give important information about the safety of systemic delivery
of adult stem cells in DMD patients. This trial will also hope-
fully answer some questions regarding the capability of donor
stem cells to migrate towards regenerating muscles and undergo
myogenic differentiation, by producing dystrophin.
In the last few years there is a growing interest about the ther-
apeutic prospective offered by pluripotent stem cells. Embryonic
Stem (ES) cells have been isolated from the inner cell mass of the
blastocyst in mouse (Evans and Kaufman, 1981; Martin, 1981)
and in human (Thomson et al., 1998), showing pluripotent fea-
tures. Mouse and human ES cells can efficiently differentiate into
the three germ layers, mesoderm, ectoderm and endoderm and
a consistent number of studies showed their myogenic differen-
tiation potential in vitro and in vivo (Bhagavati and Xu, 2005;
Barberi et al., 2007; Filareto et al., 2012). The therapeutic use of
ES cells has been strongly debated in the scientific community,
mainly because of limitations linked to immune rejection and
ethical concerns. However, part of these obstacles has been over-
come by a pioneering study of Yamanaka in 2006 (Takahashi and
Yamanaka, 2006) showing that induced pluripotent stem (iPS)
cells can be generated from somatic cells. In addition, a very
recent paper published in Nature showed that is possible to gener-
ate pluripotent stem cells by STAP, stimulus-triggered acquisition
of pluripotency (Obokata et al., 2014). Basically, pluripotent
conversion can be achieved by brief exposition of low-passage
source cells to acidic conditions (pH 5.7). Since STAP reprogram-
ming takes a very short period, only few days unlike transgene-
or chemical-induced iPS cell conversion, it could be clinically
relevant for tailoring cell therapy approaches.
To date, the use of iPS cells to potentially correct the dys-
trophic phenotype has been reported in several studies onmurine
(Mizuno et al., 2010; Darabi et al., 2011; Quattrocelli et al., 2011;
Filareto et al., 2013) and human iPS cells (Darabi et al., 2012).
Preclinical evidences show that myoblasts and mesenchymal cells
derived from human ES and iPS can efficiently fuse with mature
muscle fibers (Awaya et al., 2012; Goudenege et al., 2012) and
improve the performances of engrafted muscles (Darabi et al.,
2012) (Figure 2). After introduction of factor-based reprogram-
ming, generation of iPS cells is feasible from any kind of cell
population. However, iPS cells own an epigenetic memory, which
results in a biased cell-differentiation towards the cell lineage of
its source. This is probably due to the conservation of epigenetic
marks, like CpG island (CGI) methylation and histone modifica-
tions, after reprogramming (Kim et al., 2010; Polo et al., 2010).
Also iPS cells generated from murine skeletal MABs upon ter-
atoma analysis differentiated with a significantly greater efficiency
towards skeletal myocytes compared to fibroblast-reprogrammed
iPS cells (Quattrocelli et al., 2011). If the myogenic memory will
be confirmed in human iPS cells, this phenomenon could have an
unpredicted impact for future translational studies.
Overall, these evidences suggest that, although all the efforts
made so far on the use of pluripotent stem cells have been focal-
ized on dystrophinopathies, the therapeutic use of iPS and ES
cells could be an extraordinary potential clinical tool useful in the
treatment of any skeletal muscle degenerations.
NEW CHALLENGE: MICRORNAS AND THEIR THERAPEUTIC
POTENTIAL
In the early ′90 a 22 nt non-coding transcript RNA, lin-4, was
identified in C. elegans. It represses the expression of lin-14, a
nuclear protein necessary for the larval development (Lee et al.,
1993; Wightman et al., 1993). This discovery was the trigger for
thousands of subsequent publications regarding the identifica-
tion of micro inhibitory RNAs (miRNAs) in early embryogenesis
(Berardi et al., 2012) and in cardiac and skeletal myogenesis (Ge
and Chen, 2011; Crippa et al., 2012). miRNAs target sites in the
3′UTR of the mRNA leading to inhibition of mRNA transla-
tion and/or enhanced mRNA degradation, thus resulting in the
decrease of protein expression levels (Djuranovic et al., 2011).
miRNAs are generally transcribed by RNA polymerase II, as a pri-
mary miRNA (pri-miRNA)s then the RNase III enzyme Drosha
removes hairpins from pri-miRNAs generating pre-miRNAs. In
the cytoplasm, the pre-miRNA is further cleaved by the RNase III
enzyme Dicer to generate mature miRNAs.
Highly expressed miRNAs in skeletal muscle tissue are termed
myomiRs, which include miR-1, miR-133a, miR133-b, miR-206,
miR-208, miR208b, miR486, and miR-499 (Van Rooij et al.,
2008). They can be responsible for metabolic changes in skele-
tal muscle tissue (Figure 3). For example, muscular hypertrophy
in Texel sheep is caused by a point mutation in the 3′UTR of
myostatin RNA messengers, which creates a target site for miR-
1 and miR-206 (Clop et al., 2006). Those miRNAs are abundant
in the skeletal muscle tissue and can negatively affect myostatin
expression, one of the most effective repressor of muscle growth.
However, since another possible target for miR-206 is utrophin,
a valuable substitute of dystrophin, several researchers believe
that miR-206 can be responsible to sustain the dystrophic phe-
notype (Rosenberg et al., 2006). Transgenic mice for gain and
loss of function studies are necessary to shed light in those
controversies.
miRNA are also critic regulators for muscle wasting. In fact,
possible targets for miR-486 are PTEN (phosphatase and tensin
homolog) and FoxO1A, elements of the PI3/Akt pathway (Small
et al., 2010) involved in muscle wasting and apoptosis. The activ-
ity of miR-486 results in muscle hypertrophy, since it leads to
the activation of mTOR via PTEN inhibiton, and to the reduc-
tion of the ubiquitin ligase expression, which sustains atrophy in
skeletal muscle tissue. The expression profiles of miR-486 strongly
support its role in muscle homeostasis, since it is decreased in
denervated muscles and almost absent in Duchenne patients
(Eisenberg et al., 2007).
miR-1 and miR-133 modulate skeletal and cardiac mus-
cle growth and differentiation. miR-1 promotes skeletal muscle
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FIGURE 3 | The roles of miRNA in skeletal muscle homeostasis and
dysfunction. Representative scheme of the main miRNAs involved in
skeletal muscle functions. Specific miRNAs are critical for satellite cell
activation (miR-27b) or for skeletal muscle differentiation (miR-1) and can be
induced for therapeutic approaches. Other miRNAs are involved in muscle
metabolism and they are able to modulate the AKT/PI3K pathway. Two
miRNA families are peculiar for their opposite dual biological functions:
miR-669 can inhibit MyoD causing a benefit in cardiac progenitors but in the
same time reduced myogenic potential in skeletal muscle progenitors;
miR-206 can induce hypertrophy by targeting mutated 3′UTR of myostatin
messengers and can sustain dystrophic phenotype by inhibiting utrophin
expression.
differentiation by targeting the histone deacetylase 4 (HDAC4),
that in turn represses Mef2C, an essential muscle transcription
factor. On the contrary, miR-133 stimulates myoblast prolifera-
tion by targeting SRF (Chen et al., 2006), whilemiR-206 promotes
myoblast differentiation targeting the mRNA of PolA1 (Kim et al.,
2006), a DNA polymerase subunit. MyoD and myogenin can
regulate miR-206 expression by binding specific elements in the
enhancer region upstreammiR-206 gene. Overexpression of miR-
27b causes premature differentiation of muscle satellite cells: once
myoblasts exit the cell cycle, miR-27 indeed targets the 3′UTR of
Pax3 (Crist et al., 2009).
The fine-tuned expression of miR-499 and miR-208b plays a
role in the control of skeletal muscle performance. In response
to calcium signaling, miR-208b and miR-499 indeed reinforce
slow fiber conversion by inducing the expression of β -MHC and
Myh7b (Van Rooij et al., 2009). They were considered initially as
MyomiRs since they are encoded by introns of their host myosin
genes Myh7 and Myh7b. These two intronic miRNAs target the
transcriptional repressors of slowmyofiber genes, including Sox6,
Purβ, Sp3, and HP-1β, (Van Rooij et al., 2009). Recently, we have
also identified a microRNA family, called miR-669, involved in
the muscle lineage switch (Crippa et al., 2011) and used them
as therapeutic molecules for long term treatments (Quattrocelli
et al., 2013) in an animal model of limb girdle muscular dys-
trophy type 2E. Up to now, crucial information concerning the
effects of miR669 in human setting for cardiac and skeletal muscle
differentiation are still missing.
In summary, the possibility to increase the pool of myogenic
stem cells, induce hypertrophy or reduce atrophic cell signaling
by the perturbation of miRNA expression profiles offers a new
opportunity to re-establish the skeletal muscle homeostasis lost
in the wide range of muscolo-skeletal disorders (Figure 3).
CONCLUDING REMARKS
In conclusion, stem cell research will ride the third millennium
as highlighted by the Nobel Prize in Physiology or Medicine 2012
jointly conferred to John Gurdon and Shinya Yamanaka for their
discoveries on cell reprogramming which paved the way for new
therapeutic horizons. We accumulated evidences that stem cell
therapy with donor adult cells has produced dramatic ameliora-
tion in dystrophic mice and dogs. However, their finite lifespan
and replication capacity, limit their therapeutic potential. Several
types or subtypes of resident stem cells have been isolated and
characterized from adult skeletal muscles. Further translational
studies are still necessary to get molecular insights on how to
improve the myogenic potential of each cell type. Moreover, it
will be relevant to reveal the molecular and epigenetic signatures
of myogenic progenitors to identify all molecules involved in the
crosstalk among the different pools. In addition, several articles
have documented a subset of miRNAs that regulate myogenic
cell proliferation, differentiation, and contractility. The possibil-
ity to improve myogenic commitment of stem cells by targeting
the expression of specific miRNAs is now implicated in several
preclinical studies (Crippa et al., 2012). New insights into addi-
tional mechanism of post-transcriptional regulation mediated by
lncRNAs are desirable since they have an impact on the distribu-
tion of miRNA molecules on their targets (Twayana et al., 2013).
In the following years miRNA technologies combined to stem cell
treatments will test novel therapeutic strategies for skeletal muscle
disorders.
Muscle progenitors may be generated from patient iPS cells,
genetically modified, systemically injected, then recruited to and
integrated in the areas of damage. This would circumvent prob-
lems related to allogeneic transplantation and difficulty in obtain-
ing autologous stem cells. The novel reprogramming methods
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(Obokata et al., 2014) do not require nuclear transfer or genetic
manipulation and thus they are more suitable for translational
studies with clinical implications. It is interesting that such a
great potential has not been explored yet in cachexia and sar-
copenia, where it could be employed avoiding genetic manipu-
lation. However, the enormous research impetus on regenerative
medicine and stem cell-based therapy could strongly influence
the future scientific directions. Emerging literature supports the
hypothesis that downregulating myonuclear apoptosis might pre-
serve muscle mass and function in the elderly. In principle,
employing pharmacological or genetic interventions to target
muscle protein turnover, autophagy andmyogenic stem cell func-
tion may provide a more thorough protection against muscle
aging and atrophy. These multi-therapeutic approaches will face
several challenges, including the clear determination of feasible
therapeutic windows for each specific intervention, especially if
systemic delivery is employed. Nevertheless, pursuing this path
is certainly worth in order to relieve the individual and societal
burden associated with muscular degeneration.
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